News 
Market Data 
Discover
Replies to post #13744 on Generex Biotechnology Corp. (fka GNBTQ)
crap is still crap no matter how you package it.there ae37 was no good sat on the shelf for 10 years now they gave it a new name li key. and its still crap.
The addition of Keytruda is really smart. AE37 is a vaccine which results in an immune reaction against a specific target protein expressed on breast cancer cells. Keytruda is an antibody which blocks a cell receptor on cancer cells so they cannot hide from AE37's immune reaction. That's what we call synergy, my friends, and it is enough to make a molecular biology nerd feel all tingly.
If you know anything about triple negative breast cancer and the sparsity of options available to this subgroup, this number should make your jaw drop to the floor. 89% disease-free survival at 55 months in the AE37 vaccine group compared with 0% in the control group. Now add Keytruda. Both of these therapies are very well tolerated by patients, and in my opinion, if the company can prosecute these expensive trials in an efficient fashion then AE37 + Keytruda will be standard of care for TNBC within the next few years.
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
Results: There were no clinicopathologic differences between groups in the 298 enrolled pts (VG = 153, CG = 145). The vaccine is safe and well tolerated. After a median f/u of 55 mo, there was a trend toward improved DFS in the VG among stage IIB/III pts (VG, n = 73, DFS 82% vs CG, n = 61, 67%, HR = 0.48, p = 0.06) and those with low HER2 expression (HER2 LE, VG, n = 68, 89% vs CG, n = 66, 51%, HR = 0.47, p = 0.1). Improved DFS in the VG was documented in patients with both stage IIB/III disease and HER2 LE (VG, n = 39, 90% vs CG, n = 38, 32%, HR 0.3, p = 0.02) and triple negative (TNBC) pts (VG, n = 21, 89% vs CG, n = 21, 0%, HR 0.26, p = 0.05).
04/14/21 10:52 AM
